shape1
shape2

mRNA Vaccines and Therapeutics Market Value - By Route of Administration (IV Infusion, Subcutaneous); By Disease Type (Hereditary Transthyretin-mediated Amyloidosis Genetic, Acute Hepatic Porphyria, Primary Hyperoxaluria Type 1, Atherosclerotic Cardiovascular Disease); By End-user Type (Research Institutes, Hospitals and Clinics); By Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa); – Global Crises Impact, Growth Analysis, Share Statistics & Forecast Report, 2024-2032

  • ID: 658 |  
  • Published date: July, 2024  |  
  • Report Format: PDF

Recent update: Our research team is keeping a close eye on the potential impact of COVID-19 and other global crises on various industries worldwide, allowing us to stay ahead of the competition.

Global Revenue Statistics

mRNA Vaccines and Therapeutics Market value is projected to witness substantial growth in the coming years. According to our research, the market size was valued at more than USD 1.27 Billion in 2023 and is expected to exhibit a CAGR of over 27.52% during the forecast period of 2024-2032. By the end of 2032, the market is expected to reach a valuation of around USD 14.45 Billion.

mRNA Vaccines and Therapeutics Market

To get more info about this report - 

Covid-19 Pandemic Impact on mRNA Vaccines and Therapeutics Market

COVID-19 has increased human suffering, weakened the economy, upended the lives of billions of people worldwide, and had a significant impact on the health, economic, environmental, and social domains. According to the World Health Organization (WHO), COVID-19 had infected over 82 million people and killed over 1.8 million as of December 31, 2020. Supply chain (SC) management (SCM) has had significant issues dealing with an unexpected demand for certain products when simultaneous travel and production restrictions have been enforced since the beginning of the global outbreak in March and is still attempting to recover from this. Companies are working to adapt to the new situation and will almost certainly face changes that will last long after the pandemic has passed.

Furthermore, the resilience challenge has been addressed in distinctly different ways by various industries. As resilience leaders, healthcare providers stand out. They used the most comprehensive set of metrics, with 60% of healthcare respondents saying they had regionalized their supply chains and 33% saying they had moved production closer to end markets.

mRNA Vaccines and Therapeutics Market Value Insights

Report Coverage

Details

Base Year

2023

Market Size in 2023

USD 1.27 Billion

Forecast Period

2024 to 2032

CAGR (2024 to 2032)

27.5%

Forecast Year Value, 2032

USD 14.45 Billion

Historical Data for

2019 to 2023

Segment Covered

By Route of Administration, Disease Type, End-user Type, Regions

Companies Covered

  • CureVac SE
  • Ethris GmbH
  • Bohringer Ingelheim International GmbH
  • Arcturus
  • Daiichi Sankyo
  • GSK Plc.
  • Kernal Biologics Inc
  • Sanofi
  • Argos Therapeutics Inc
  • Charoen Pokphand Group
  • AIM Vaccine Corporation
  • Gennova Biopharmaceuticals Limited
  • Moderna Inc.
  • BioNTech SE
  • Pfizer Inc.

 

To get more info about this report - 

Research Methodology of Global mRNA Vaccines and Therapeutics Market

At Market Value Insights, we have conducted an extensive analysis of the mRNA Vaccines and Therapeutics Market, utilizing a 360-degree approach that incorporates both primary and secondary research methods. This comprehensive approach has allowed us to gain a deep understanding of the current market dynamics, including the supply-demand balance, pricing trends, product preferences, customer behaviors, and other key factors.

Our primary research efforts were focused on gathering insights from industry professionals and opinion leaders from around the globe. This helped us to further validate our findings and gain a more well-rounded perspective of the market. To ensure the accuracy and reliability of our data, we employed a variety of market estimation and data validation techniques. Additionally, we have developed a proprietary model for internally generated data that forecasts market growth until 2032

By utilizing these research methods, we are able to provide our clients with a comprehensive understanding of the mRNA Vaccines and Therapeutics Market, allowing them to make informed business decisions and stay ahead of the curve.

Regional Analysis: Rising product demand across the North America region

mRNA Vaccines and Therapeutics Market Size

To get more info about this report - 

North America region is expected to register XX% share of global mRNA Vaccines and Therapeutics Market by 2032 due to the presence of major players in this region and adoption of advanced technologies across the region contribute to the business growth. Moreover, The United States is the most significant country in terms of technology, and industrial advancement in region, accounting for more than half of the North America region.

Asia Pacific mRNA Vaccines and Therapeutics Market is projected to attain over XX% CAGR during the forecast period. The growth in the region is attributed to the favorable government regulation and growing industrialization in the region. Furthermore, Presence of growing economies in this region such as China, India etc. are expected to contribute to the growth of the over the forecast period FPC.

Top players in the global mRNA Vaccines and Therapeutics Market include

  • CureVac SE
  • Ethris GmbH
  • Bohringer Ingelheim International GmbH
  • Arcturus
  • Daiichi Sankyo
  • GSK Plc.
  • Kernal Biologics Inc
  • Sanofi
  • Argos Therapeutics Inc
  • Charoen Pokphand Group
  • AIM Vaccine Corporation
  • Gennova Biopharmaceuticals Limited
  • Moderna Inc.
  • BioNTech SE
  • Pfizer Inc.

To get more info about this report - 

In-depth analysis of mRNA Vaccines and Therapeutics Market along with industry coverage and forecasting for the following segments:

Market Value, By Route of Administration

  • IV Infusion
  • Subcutaneous

Market Value, By Disease Type

  • Hereditary Transthyretin-mediated Amyloidosis Genetic
  • Acute Hepatic Porphyria
  • Primary Hyperoxaluria Type 1
  • Atherosclerotic Cardiovascular Disease

Market Value, By End-user Type

  • Research Institutes
  • Hospitals and Clinics

Market Value, By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions (FAQ):

Publisher: Market Value Insights

  • PURCHASE OPTION

  • $2500

  • $3500
  • $4500

Get in Tuch With Us